Serum soluble ST2 is a potential long-term prognostic biomarker for transient ischaemic attack and ischaemic stroke.

Increased serum sST2 levels in TIA/ischaemic stroke were associated with increased risks of poor outcome within 90 days and 1 year, suggesting that serum sST2 may be a potential long-term prognostic biomarker for TIA/ischaemic stroke.